Press Release: Basilea reports positive interim -2-

tumor-infiltrating macrophages and improves response to T cell checkpoint

immunotherapy in pancreatic cancer models. Cancer Research 2014 (74),

5057-5069

9. E. Peranzoni, J. Lemoine, L. Vimeux et al. Macrophages impede CD8 T cells

from reaching tumor cells and limit the efficacy of anti--PD-1 treatment.

Proceedings of the National Academy of Science of the United States of

America 2018 (115), E4041-E4050

10. V. Mazzaferro, B. F. El-Rayes, M. Droz dit Busset et al. Derazantinib

(ARQ 087) in advanced or inoperable FGFR2 gene fusion-positive

intrahepatic cholangiocarcinoma. British Journal of Cancer 2019 (120),

165-171. ClinicalTrials.gov identifier: NCT01752920

11. FIDES-02: ClinicalTrials.gov identifier: NCT04045613

12. FIDES-03: ClinicalTrials.gov identifier: NCT04604132

13. S. K. Saha, A. X. Zhu, C. S. Fuchs et al. Forty-year trends in

cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the

rise. The Oncologist 2016 (21), 594-599

14. A. Lamarca, D. H. Palmer, H. S. Wasa et al. ABC-06 | A randomised phase

III, multi-centre, open-label study of Active Symptom Control (ASC) alone

or ASC with oxaliplatin/5-FU chemotherapy (ASC+mFOLFOX) for patients

(pts) with locally advanced/metastatic biliary tract cancers (ABC)

previously-treated with cisplatin/gemcitabine (CisGem) chemotherapy.

Journal of Clinical Oncology 2019 (37), supplement, abstract 4003

Attachment

-- Press release (PDF)

https://ml-eu.globenewswire.com/Resource/Download/471f41af-237d-44b8-a56c-f9b331dbb794

(END) Dow Jones Newswires

March 24, 2021 02:15 ET (06:15 GMT)